Rationale for Categorizing Hydrocodone Combination Products as Schedule III

Published Online: Monday, January 20, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
 
This is the fifth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Ashley Huntsberry and Joselyn Benabe from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences competed against a record number of participants to win the 19th annual ASHP National Clinical Skills Competition SM, held December 7, 2014, during the ASHP Midyear Clinical Meeting in Anaheim, CA.
Binita Patel, PharmD, MS, explains the role telehealth and telepharmacy will play in patient management.
Binita Patel, PharmD, MS, discusses how provider status would affect reimbursement models in ambulatory pharmacy.
Binita Patel, PharmD, MS, discusses how pharmacists can prepare for threats to the current ambulatory care model.
Latest Issues
$auto_registration$